CSPC Pharmaceutical Group Limited — Earnings Release 2001

Apr 22, 2002

Listed Company Information

CHINA PHARMA<01093> - Results Announcement (Summary) China Pharmaceutical Enterprise and Investment Corporation Limited announced on 22/4/2002: (stock code: 1093) Year end date: 31/12/2001 Currency: HKD Auditors' Report: Neither Review of Interim Report by: N/A (Audited) (Audited) Last Current Corresponding Period Period from 1/1/2001 from 1/1/2000 to 31/12/2001 to 31/12/2000 Turnover : 1,168,244,000 995,096,000 Profit/(Loss) from Operations : 192,819,000 128,639,000 Finance cost : (27,102,000) (29,843,000) Share of Profit/(Loss) of Associates : - (290,000) Share of Profit/(Loss) of Jointly Controlled Entities : 5,183,000 3,779,000 Profit/(Loss) after Tax & MI : 140,006,000 80,473,000 % Change over Last Period : +74% EPS/(LPS)-Basic : 11.29 CENTS 6.49 CENTS -Diluted : 11.10 CENTS 6.40 CENTS Extraordinary (ETD) Gain/(Loss) : - - Profit/(Loss) after ETD Items : 140,006,000 80,473,000 Final Dividend per Share : 3.6 CENTS Nil (Specify if with other options) : - - B/C Dates for Final Dividend : 21/5/2002 to 27/5/2002 dbi Payable Date : 7/6/2002 B/C Dates for Annual General Meeting : 21/5/2002 to 27/5/2002 dbi Other Distribution for Current Period : - B/C Dates for Other Distribution : N/A Remarks: 1. Profit from operations 2000 2001 HK$ HK$ Profit from operations has been arrived at after charging (crediting): Amortisation of intangible assets 15,255,000 13,250,000 Depreciation of property, plant and equipment 88,715,000 82,348,000 Allowance for doubtful debts 9,600,000 12,030,000 Impairment loss on property, plant and equipment 3,543,000 17,250,000 Gain on disposal of subsidiaries (4,051,000) - Bank interest income (1,238,000) (5,210,000) Interest income from loan receivables (900,000) (1,425,000) ============ ========== 2. Earnings per share The calculation of the basic and diluted earnings per share is based on the following data: 2001 2000 Profit attributable to shareholders HK$140,006,000 HK$80,473,000 ============== ============== Weighted average number of ordinary shares for the purpose of basic earnings per share 1,240,447,279 1,240,429,301 Effect of dilutive potential ordinary shares in respect of share options 20,934,321 16,000,000 ______________ ______________ Weighted average number of ordinary shares for the purpose of diluted earnings per share 1,261,381,600 1,256,429,301 ============== ============== The computation of diluted earnings per share does not assume the exercise of the Company's outstanding warrants as the exercise price of those warrants was higher than the fair value of the shares throughout the year ended December 31, 2000 and until the date of expiration of the warrants in October 2001.